CC
| |
Checkpoint Capital L.P.13F | |
| Checkpoint Capital L.P. | |
| Last update 2025-05-15 | 14 Stocks (5 new) |
| Value $182.00 Mil | Turnover 32 % |
Checkpoint Capital L.P. Top Holdings of 2025-03-31
View Full List
| Ticker | | Company | Shares | Value ($1000) | Shares Change % | Weighting % | Trade Impact % | % of Shares outstanding | 3M Change % | YTD Change % | Market Cap $Mil | Industry |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ARGX | argenx SE | 115,000 | 68,064.5 | +24.32% | 37.340 | +7.31% | 0.190 | -0.80% | -11.29% | 33,300.1 | Biotechnology | |
RYTM | Rhythm Pharmaceuticals Inc | 907,240 | 48,056.5 | +24.62% | 26.370 | +5.21% | 1.430 | +20.55% | +18.35% | 4,215.2 | Biotechnology | |
RVMD | Revolution Medicines Inc | 392,011 | 13,861.5 | +86.67% | 7.610 | +3.53% | 0.210 | +18.47% | -14.95% | 6,929.2 | Biotechnology | |
SLNO | Soleno Therapeutics Inc | 172,902 | 12,353.9 | +146.91% | 6.780 | +4.03% | 0.340 | +21.88% | +88.83% | 4,277.4 | Biotechnology | |
IRON | Disc Medicine Inc | 243,311 | 12,078.0 | +31.52% | 6.630 | +1.59% | 0.700 | +36.22% | -15.77% | 1,849.5 | Biotechnology | |
PTGX | Protagonist Therapeutics Inc | 175,184 | 8,471.9 | New Holding | 4.650 | +4.65% | 0.280 | +16.63% | +30.56% | 3,123.6 | Biotechnology | |
STOK | Stoke Therapeutics Inc | 730,717 | 4,859.3 | +139.28% | 2.670 | +1.55% | 1.340 | +93.68% | +5.53% | 635.5 | Biotechnology | |
SEPN | Septerna Inc | 824,878 | 4,776.0 | New Holding | 2.620 | +2.62% | 1.850 | +105.70% | -51.67% | 493.1 | Biotechnology | |
KYMR | Kymera Therapeutics Inc | 136,605 | 3,738.9 | +76.18% | 2.050 | +0.89% | 0.210 | +100.41% | +9.64% | 3,094.6 | Biotechnology | |
TCRX | TScan Therapeutics Inc | 2,017,650 | 2,784.4 | +14.90% | 1.530 | +0.20% | 3.570 | +16.67% | -51.64% | 83.2 | Biotechnology |
Checkpoint Capital L.P.'s Historical Top Holdings Breakdowns
Checkpoint Capital L.P.'s Top Stock Picks
View Full List
| Ticker | | Company | Date | Action | Impact % | Price Range | Price | Price Change from Avrg% | Comment | Current Shares | Share Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
PHAT | Phathom Pharmaceuticals Inc | 2025-03-31 | Sold Out Sold Out | -9.40% | 4.22 ($6.07) 7.74 | $8.37 | 37.89% | Sold Out | 0 | -2,274,157 | |
AXSM | Axsome Therapeutics Inc | 2025-03-31 | Sold Out Sold Out | -7.53% | 80.05 ($113.93) 137.75 | $106.91 | -6.16% | Sold Out | 0 | -174,769 | |
ARGX | argenx SE | 2025-03-31 | Add Add | +7.31% | 571 ($631.12) 671.75 | $545.58 | -13.55% | Add 24.32% | 115,000 | 22,500 | |
AVDL | Avadel Pharmaceuticals PLC | 2025-03-31 | Sold Out Sold Out | -5.37% | 7.49 ($8.37) 11.06 | $8.82 | 5.38% | Sold Out | 0 | -1,004,790 | |
RYTM | Rhythm Pharmaceuticals Inc | 2025-03-31 | Add Add | +5.21% | 48.56 ($55.48) 61.02 | $66.25 | 19.42% | Add 24.62% | 907,240 | 179,258 | |
PTGX | Protagonist Therapeutics Inc | 2025-03-31 | New Buy New Buy | +4.65% | 35.09 ($41.9) 59.76 | $50.40 | 20.27% | New holding | 175,184 | 175,184 | |
SLNO | Soleno Therapeutics Inc | 2025-03-31 | Add Add | +4.03% | 42.54 ($48.69) 71.99 | $84.88 | 74.33% | Add 146.91% | 172,902 | 102,875 | |
PLRX | Pliant Therapeutics Inc | 2025-03-31 | Sold Out Sold Out | -3.59% | 1.35 ($6.07) 13.53 | $1.21 | -80.07% | Sold Out | 0 | -535,494 | |
RVMD | Revolution Medicines Inc | 2025-03-31 | Add Add | +3.53% | 35.36 ($40.59) 44.42 | $37.20 | -8.35% | Add 86.67% | 392,011 | 182,011 | |
SEPN | Septerna Inc | 2025-03-31 | New Buy New Buy | +2.62% | 5.52 ($11.42) 23.69 | $11.07 | -3.10% | New holding | 824,878 | 824,878 |
Checkpoint Capital L.P. Total Holding History ($B)
Checkpoint Capital L.P.'s Asset Allocation
Checkpoint Capital L.P. Past Portfolios
| Portfolio Date | Number of Stocks | New Stocks | Total Value ($Mil) | Q/Q Turnover |
|---|---|---|---|---|
Top Ranked Articles
- 1
Checkpoint Capital L.P.'s Hypothetical Growth since 2025-03-31
Checkpoint Capital L.P.'s Yearly Returns
| Year | Portfolio % | % | Excess Gain % |
|---|
Checkpoint Capital L.P.'s Holdings Heat Map
Size field:
Checkpoint Capital L.P.'s Holdings Bubble Chart
Checkpoint Capital L.P. News
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers